Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic

Smaranika Rahman1, Md. Jamal Hossain2, Zabun Nahar1, Mohammad Shahnar1, Mohiuddin Ahmed Bhuiyan1 and Md. Rabiu Islam1

1Department of Pharmacy, University of Asia Pacific, Farmgate, Dhaka, Bangladesh. 2Department of Pharmacy, State University of Bangladesh, Dhanmondi, Dhaka, Bangladesh.

ABSTRACT: The COVID-19 pandemic has become the most devastating pandemic of the 21st century since its appearance in December 2019. Like other RNA viruses, continuous mutation is common for coronavirus to create several variants and subvariants. The main reason behind this mutation and evolvement of SARS-CoV-2 was its structural spike (S) glycoprotein. Coronavirus has become a threat to global public health due to its high mutation capability and antibody neutralizing capacity. According to the World Health Organization (WHO), there are 5 major variants of concern (VOC) are Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529). Recently, different Omicron subvariants have gained worldwide dominance, such as BA.1, BA.2, BA.3, BA.4, and BA.5. However, there is a discernible drop in this symptomatic sickness globally due to the success of numerous monoclonal antibodies and vaccinations. Here we also discussed the currently dominant Omicron subvariants and the effectiveness of antiviral agents and vaccines. Based on the available data and our knowledge, we can suggest that the global healthcare organizations can decide on the declaration of the end of the pandemic phase of COVID-19 soon; however, the covid-19 will continue.

KEYWORDS: SARS-CoV-2, SARS-CoV-2 subvariants, COVID-19, public health

BACKGROUND

Coronaviruses belong to a class of encapsulated positive single-stranded RNA viruses that have a diverse spectrum of natural hosts. They can infect a wide range of animals and humans.1,2 Tyrrell and Bynoe isolated the viruses from the common-cold patients and later gave them the name coronavirus in 1966 for their crown-like appearance.3 The first SARS-CoV virus emerged suddenly in China in 2002 to 2003 that killed 813 of 8,809 affected people in 29 countries or regions.4 After that, in 2012, the MERS-CoV emerged as a human disease with a high case-fatality rate.5 The ongoing COVID-19 is the largest zoonotic pandemic after the Spanish influenza pandemic.6 It was initially called Wuhan pneumonia due to the location and pneumonia symptoms. The World Health Organization (WHO) renamed this viral infection “COVID-19” on February 12, 2020.7 The International Committee on Taxonomy of Viruses (ICTV) proposed this virus as SARS-CoV-2 since it belongs to the severe acute respiratory syndrome-associated coronavirus category.8 The SARS-CoV-2 virus has been evolving since its discovery in December 2019. As several variants are developing around the world, the WHO classified those variants as variants of concern (VOC), variants under monitoring (VUM), and variants of interest (VOI).9

SARS-CoV-2 Variants and Subvariants

RNA viruses are more likely than DNA viruses to develop variants. COVID-19 replication is widespread since it is an RNA virus.10 In this case, the structural spike (S) glycoprotein plays the most important role, and mutations in this S-glycoprotein led to the emergence of VOC by increasing angiotensin-converting enzyme-2 (ACE-2) receptor affinity, resistance to neutralizing antibodies, viral replication, infectivity, higher transmissibility, and immune escape, resulting in increased reinfection risk and severity of reinfection.11 Five reported VOCs are: Alpha (B.1.1.7; UK, Sep-2020); Beta (B.1.351; South Africa, May-2020); Gamma (P.1; Brazil, November 2020); Delta (B.1.617.2; India, October 2020); and Omicron (B.1.1.529; several countries, November 2021).5,12,13

Among the 5 VOCs, the Omicron has a unique feature with a total of 30 signature mutations.13 Among them, 23 are bold-faced mutations.13 These mutations are different from others variants.13 The percentage of Omicron infection in Africa reached ∼90% within the first 25 days after the first identification in November 2021. However, we have seen the Beta variant responsible for ∼50% infection rate within roughly 100 days, and the Delta variant contributed ∼80% infection within approximately 100 days.14 According to an artificial intelligence (AI) model, the Omicron variant was

SAGE
thought to be 2.8 times more transmissible than the Delta, eluding current immunizations by nearly 90% and drastically reducing monoclonal antibody efficacy (mAbs). Until January 8, 2022, it was distributed in 150 countries or territories, resulting in 552,191 confirmed cases and 115 deaths.  

Omicron has 5 sublineages such as BA.1, BA.2, BA.3, BA.4, and BA.5. The ancestral lineage of the Omicron variant appears to be B.1.1.529, followed by the BA.1 sublineage, which looks to be the most similar to B.1.1.529 and BA.3 is the combined form of BA.1 and BA.2 sublineages. A study revealed that BA.1 has 37 mutations in the spike protein, BA.2 has 31 mutations, and BA.3 has 33 mutations with 21 common mutations in all 3 lineages. The receptor-binding domain (RBD) interacts with host ACE-2 to induce infection. Also, it is a prominent target for vaccines and antiviral drug development. There are 15 mutations in RBD of Omicron BA.1 subvariants, whereas we observed 12 mutations in RBD of Omicron BA.2 and BA.3 variants. Also, there are some common mutations among the sub-variants of Omicron. According to a study by Chen and Wei, the BA.2 subvariant of Omicron is 1.5 and 4.2 times more infectious than BA.1 subvariants and Delta variants, respectively. It also revealed that it has a 30% higher chance of eluding current immunizations than BA.1 and the reinfection capacity of the patients who had recovered from BA.1. BA.2 Omicron is also known as the stealth Omicron because its genetic alterations make it difficult to distinguish from Delta using PCR testing. According to the WHO, it is now the most prevalent strain of COVID-19 worldwide and the virus’s most transmissible version to date.  

The WHO categorized BA.4, BA.5 (BA.1 and BA.2 sister lineages), and a few other BA.2 sublineages as VOC sublineages under monitoring (VOC-LUM). BA.2.12.1, BA.4 and BA.5 subvariants appear to escape antibody responses among fully vaccinated and boosted individuals and those who had previous Covid-19 infection. The WHO will review the global epidemiology of VOC-LUM and provide a separate label in case of new mutations to form conclusions concerning transmissibility, severity or vaccine effectiveness. Rather than XE, there are several other BA.1 and BA.2 recombinants, including XQ in the UK, XG in Denmark, XJ in Finland, and XK in Belgium. Furthermore, another controversial recombinant known as “Deltacron” (formally referred to as XD and XF) is usually the recombination variations of Delta and Omicron and appears to have a genetic sequence mostly identical to Delta, but with features of the spike protein from Omicron BA.1. It was originally discovered in France in mid-February, and according to the UKHSA, fewer than 40 instances of XF have been discovered, all in the UK. Although no cases of XD have been documented in the UK, 49 cases, predominantly in France, have been reported to global databases.

**Effectiveness of Potential Therapeutic Agents Against Omicron Subvariants**

Recently, Omicron BA.2 has become the most common subvariant worldwide, with recombinant subvariants; for example, XE was a dominating variant in several countries, particularly the UK. A recent study found that boosting with Pfizer or Moderna, rather than 2 doses of Pfizer or AstraZeneca, offered a significant increase in protection. On the contrary, the subvariants BA.1 and BA.2 didn’t show much effectiveness against mAbs from Eli Lilly, Regeneron, AstraZeneca, Celltrion, Rockefeller University except sotrovimab developed by GlaxoSmithKline. 

According to WHO, a new variety known as the XE subvariant has evolved and is now classified as a new VOC. Although more research and data are needed before drawing any conclusions regarding the efficacy of the current COVID-19 therapy option, there is still hope that the new recombinant versions are not as dangerous as previously thought. There were XA, XB, XC, and XD subvariants before XE, but none of them constituted a threat to global health. Furthermore, following the identification of the XE subvariant on January 19, 2022, the number of hospitalizations due to this variety did not increase significantly; however, the Delta and Omicron variants caused a catastrophic pandemic within the first 2 weeks. Moreover, according to recent data, vaccine effectiveness against symptomatic infection was 9% and 13% for BA.1 and
Table 1. Currently identified Omicron subvariants.

| OMICRON SUBVARIANTS | SPIKE PROTEIN MUTATIONS | UNIQUE MUTATION | COUNTRY AND YEAR OF DETECTION | TRANSMISSIBILITY | DISEASE SEVERITY | HOSPITALIZATION | EFFECTIVENESS OF CURRENT VACCINES AND THERAPEUTICS |
|---------------------|--------------------------|----------------|-------------------------------|------------------|-----------------|--------------|---------------------------------------------------|
| BA.1                | 142D, G339D, S373P, S375F, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q96H, N969K, H69del, V70del, T95I, V143del, Y144del, Y145del, N211L, L212V, V213R, G446S, A67V, ins214EP, R216E, S371L, G496S, T547K, N856K, L981F | A67V, ins214EP, R216E, S371L, G496S, T547K, N856K, L981F | South Africa, November-2021 | Increased than delta variants | Reduced than delta variants | About 73% reduced hospitalization rate than delta variants |
|                     |                          |                |                               |                  |                 |              | • Reduced vaccine effectiveness generated by infections or vaccination. |
|                     |                          |                |                               |                  |                 |              | • After either a second or third vaccination, there is increased neutralization activity and maturation of cross-reactive antibodies against the Omicron BA.1. |
|                     |                          |                |                               |                  |                 |              | • Resistant to the majority of antibodies. |
| BA.2                | 142D, G339D, S373P, S375F, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q96H, N969K, S371F, D405N, T19I, L24del, P25del, P26del, A27S, V213G, T376A, R408S | T19I, L24del, P25del, P26del, A27S, V213G, T376A, R408S | South Africa, November-2021 | Increased transmission rate than BA.1 | Sufficient information is not available. | Sufficient information is not available. |
|                     |                          |                |                               |                  |                 |              | • After either a second or third vaccination, there is increased neutralization activity and maturation of cross-reactive antibodies against the Omicron BA.2. |
|                     |                          |                |                               |                  |                 |              | • Among all clinically authorized monoclonal antibodies (mAbs) only bebtelovimab still effectively combats BA.2. |
| BA.3                | 142D, G339D, S373P, S375F, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q96H, N969K, H69del, V70del, T95I, V143del, Y144del, Y145del, N211L, L212V, V213R, G446S, S371F, D405N, R214del | R214del | South Africa, November-2021 | Increased transmission rate than BA.1 | Sufficient information is not available. | Sufficient information is not available. |
|                     |                          |                |                               |                  |                 |              | • Resist vaccine immunity more effectively than BA.1 and BA.2. |
|                     |                          |                |                               |                  |                 |              | • The majority of mAbs totally or substantially lost their ability to neutralize BA.3. |

(Continued)
Table 1. (Continued)

| SUBVARIANTS | SPIKE PROTEIN MUTATIONS$^{2,4}$ | UNIQUE MUTATIONS$^{24,25}$ | COUNTRY AND YEAR OF DETECTION$^{26}$ | TRANSMISSIBILITY$^{24,25,27,28}$ | DISEASE SEVERITY$^{28}$ | HOSPITALIZATION$^{28}$ | EFFECTIVENESS OF CURRENT VACCINES AND THERAPEUTICS$^{26,29-36}$ |
|-------------|---------------------------------|-----------------------------|-------------------------------------|---------------------------------|----------------------|----------------------|----------------------|
| BA.4 (BA.1 and BA.2 sister lineage) | BA.2-like constellation in the spike protein + S:del69/70, S:L452R, S:F486V, S:Q493R reversion | Beyond the spike protein: (NSP4: L438F reverted to wild type, ORF 6: D61 (wild type), ORF 7b: L11F, N: P151S) | South Africa, January-2022 | Increased transmission rate than BA.1 and BA.2 | Sufficient information is not available. | Sufficient information is not available. | • BA.4 is much (4.2-fold) more resistant, which increases the likelihood that it will result in infections that are resistant to vaccination. • Among all clinically authorized monoclonal antibodies (mAbs) only bebtelovimab still effectively combats BA.4. |
| BA.5 (BA.1 and BA.2 sister lineage) | BA.2-like constellation in the spike protein + S:del69/70, S:L452R, S:F486V, S:Q493R reversion | Beyond the spike protein: (M: D3N, ORF 7b: L11 (wild type), N: P151 (wild type), synonymous SNPs: A27038G, C27889T) | South Africa, January-2022 | Increased transmission rate than BA.1 and BA.2 | Sufficient information is not available. | Sufficient information is not available. | • Shows about 4.2-fold more resistant, which increases the likelihood that it will result in infections that are resistant to vaccination. • Among all clinically authorized monoclonal antibodies (mAbs) only bebtelovimab still effectively combats BA.4. |
| BA.2.12.1 (BA.2 sublineage) | BA.2 + S:L452Q, S:S704F | Sufficient information is not available. | United States of America, December-2021 | Sufficient information is not available. | Sufficient information is not available. | Sufficient information is not available. | • Reduced effectiveness of most of the monoclonal antibodies except bebtelovimab. |
| BA.2.75 (BA.2 sublineage) | BA.2 + S:K147E, S:W152R, S:F157L, S:I210V, S:G257S, S:D339H, S:G446S, S:N460K, S:Q493R reversion | Sufficient information is not available. | India, May-2022 | Sufficient information is not available. | Sufficient information is not available. | Sufficient information is not available. | • Sufficient information is not available. |
BA.2 subvariants, respectively. However, the rates can be improved to 63% for BA.1 and 70% for BA.2 at 2 weeks after a third booster dose. The recombination of either Omicron sublineages or Omicron and Delta sublineages is one of the new developing variations. Therefore, their effectiveness against vaccines is assumed to be the same. The effectiveness of potential therapeutic monoclonal antibodies (mAbs), antiviral agents, vaccines, and combinations of some monoclonal antibodies against recent WHO-labeled COVID-19 Omicron subvariants is shown in Table 2.

### Table 2. Effectiveness of potential therapeutic monoclonal antibodies (mAbs), antiviral agents, vaccines and combinations of some monoclonal antibodies.

| ANTIVIRAL AGENTS | ORIGINATOR | EFFECTIVENESS AGAINST CURRENT MAJOR SUBVARIANTS |
|------------------|------------|-----------------------------------------------|
| Imdevimab (REGN10987) | Regeneron | Effectively neutralized the subvariants BA.1, BA.2, BA.4 and BA.5, but reduced neutralization capacity against BA.3. |
| Casirivimab (REGN10933) | Regeneron | Reduced neutralization capacity against BA.2. |
| Bamlanivimab (LY-CoV555) | Eli Lilly | Reduced neutralization capacity against BA.2. |
| Etesevimab (CB6/LY-CoV016) | Eli Lilly | Reduced neutralization capacity against BA.2. |
| Sotrovimab (S309) | GSK and Vir Biotechnology | Enable potential neutralization of BA.1 and BA.2 subvariants, but showed decreased activity against BA.4 and BA.5 subvariants. |
| Cilgavimab (COV2-2130) | AstraZeneca | Effectively neutralized the subvariants BA.2, BA.4, and BA.5 but showed complete loss of effectiveness against BA.1. |
| Tixagevimab (COV2-2196) | AstraZeneca | Reduced neutralization activity against BA.4 and BA.5 subvariants. |
| Regdanvimab (CT-P59) | Celltrion | Reduced neutralization capacity against BA.2. |
| Amubarvimab (BRil-196) | Brii Biosciences | Reduced neutralization capacity against BA.2. |
| Bebtelovimab (LY-CoV1404) | AbCellera and Eli Lilly | Effectively neutralized the subvariants BA.2, BA.2.12.1, BA.4, and BA.5. |
| Adintrevimab (ADG-2) | Adagio Therapeutics | Enable potential neutralization of BA.1 and BA.2 subvariants, but showed decreased activity against BA.3, BA.4, and BA.5 subvariants. |
| Remdesivir (GS-5734) | Gilead Sciences | Improved efficacy as early treatment against these new circulating variants, but with 3days of intravenous administration. Reduced efficacy against BA.4 and BA.5 subvariants. |
| Molnupiravir | Merk and co. | Because of its efficacy and safety issues, it is only recommended as an emergency treatment option. Reduced efficacy against BA.4 and BA.5 subvariants. |
| BNT162b2 mRNA vaccine | Pfizer–BioNTech | Significant increase in effectiveness against BA.1 and BA.2 subvariants after third booster dose. |
| CoronaVac (RBD protein (ZF2001)) | Sinovac Biotech | BA.1 and BA.2 showed no significant difference in resistance to neutralization by plasma after 6months of second dose, whereas BA.4 and BA.5 exhibited increased immune-evasion capability. Moreover, vaccinated people previously infected with COVID-19 showed a marked decrease in neutralization of BA.2, BA.3, BA.4, and BA.5. |
| ChAdOx1 | AstraZeneca | Significant effectiveness against omicron variants after second dose but the effectiveness is short-lived which require booster dose. |
| mRNA-1273 | Moderna | Significant effectiveness against omicron variants after second dose but the effectiveness is short-lived which require booster dose. |
| JNJ-78436735 | Johnson & Johnson | Significant effectiveness against omicron variants after second dose but the effectiveness is short-lived which require booster dose. |
| Evusheld (cilgavimab and tixagevimab) | AstraZeneca | Improved efficacy against BA.2, but BA.4 and BA.5 showed about 20-fold resistance to Evusheld especially to cilgavimab. |
| BRII-196 and BRII-198 cocktail (amubarvimab plus romlusevimab) | Brii Biosciences | Effectively neutralized the subvariants BA.3, BA.4, and BA.5. |
| Casirivimab and imdevimab | Regeneron | Increased neutralizing activity against BA.4 and BA.5 subvariants. |
Ending of Pandemic Phase and Moving Back to Regular Life

Healthcare systems, educational institutions and communities, and the global economy have faced a devastating situation since the introduction of the ongoing COVID-19 pandemic. The world has been dealing with the devastating pandemic crisis created by the 5 most hazardous VOCs by expanding vaccination facilities and raising public awareness about health safety guidelines. Year 2020 was challenging to approach therapeutic options and develop vaccines against COVID-19. In 2021, the world has got several effective vaccines and anti-viral drugs to fight coronavirus. Countries across the world are giving third or booster doses of vaccines, and the Omicron variant has infected a huge population worldwide. In earlier, we assumed that the pandemic phase of COVID-19 will end after the massive wave due to the Omicron variant. The present global SARS-CoV-2 immunity is at a high level than ever by the combined effect of natural immunity and vaccination efforts. However, there might have chances to evolve some deadly new variants of SARS-CoV-2 in the close future. Some countries might face rising peaks of SARS-CoV-2 transmission during their winter months. Moreover, we have some lessons from the earlier influenza pandemics and we know how the earlier deadly pandemics were brought under control. Therefore, healthcare authorities across the world need to revise and update their responses to the COVID-19 pandemic. They can emphasize new molecular, phylogenetic, and pathogenetic insights to explain and understand the efficacy of current vaccines and the potential risk of new variants. Also, they should consider the declaration of the end of the pandemic phase of COVID-19 based on the previous experiences, present lessons, and nature of the coronavirus variants.

However, the future SARS-CoV-2 variants and subvariants might have less impact on humans. The healthcare authorities and people will face future waves with updated vaccines, improved antivirals, and well-adopted preventive techniques. Special countermeasures need to take for the vulnerable populations during the COVID-19 waves. Therefore, we can expect that the COVID-19 pandemic will be ended soon to turn back to regular life. Our healthcare systems will develop and adopt effective policies to manage future COVID-19 waves. The extra precautionary period of COVID-19 will be over soon. Therefore, the international healthcare authorities should prepare an integrated action plan to end the pandemic phase of COVID-19. They should take more initiatives to engage the general population in vaccination programs and health safety measures. Also, they should take an activity plan for research and closely observe the viral mutations to assess the impact of new variants on human health. Moreover, they should support fragile healthcare systems to protect the health of every person from any future pandemics across the world.

Author Contributions

Smarnanika Rahman, Md. Jamal Hossain, and Zuban Nahar reviewed articles, collected information and wrote the first draft. Mohammad Shahriar and Mohiuddin Ahmed Bhuiany edited the manuscript, gave intellectual inputs in the revised manuscript. Md. Rabiatul Islam supervised the whole work and revised the manuscript. All the authors reviewed and approved the final submission.

Disclosures and Ethics

Not applicable to this article.

REFERENCES

1. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011;81: 85-164.
2. Mohapatra RK, Tiwari R, Sarangi AK, Islam MR, Chakraborty C, Dhma K. Omicron (B.1.1.529) variant of SARS-CoV-2: concerns, challenges, and recent updates. J Med Virol. 2022;94:2316-2342.
3. Tyrrell DA, Byrnes ML. Cultivation of viruses from a high proportion of patients with colds. Lancet. 1966;1:77-77.
4. Moreno DM, Brennan JG, Calleja CH, et al. The origin of COVID-19 and why it matters. Am J Trop Med Hyg. 2020;103:955-959.
5. Ahmammad I, Hossain MU, Rahman A, et al. Wave-wise comparative genome study for revealing the complete scenario and dynamic nature of COVID-19 pandemic in Bangladesh. PLoS One. 2021;16:e0258019.
6. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med. 2002;76:105-115.
7. Liu YC, Kuo RL, Shih SR. COVID-19: the first documented coronavirus pandemic in history. Biomed J. 2020;43:528-333.
8. Dhma K, Khan S, Tiwari R, et al. Coronavirus disease 2019-COVID-19. Clin Infect Dis. 2020;3:30028.
9. World Health Organization. Tracking SARS-CoV-2 variants. 2022. Accessed June 24, 2022. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
10. Lutting AS, Hodcroft EB. Genetic variants of SARS-CoV-2-What do they mean? J Med Virol. 2021;93:529-531.
11. Hirabara SM, Serdan TDA, Gorjao R, et al. SARS-CoV-2 variants: differences and potential of immune evasion. Front Cell Infect Microbiol. 2021;11:781429.
12. Rahman FI, Ether SA, Islam MR. The “Delta Plus” COVID-19 variant has evolved to become the next potential variant of concern: mutation history and measures of prevention. J Clin Physiol Pharmacol. 2021;33:109-112.
13. Sohan M, Hossain MJ, Islam MR. The SARS-CoV-2 omicron (B.1.1.529) variant and effectiveness of existing vaccines: What we know so far. J Med Virol. 2022;94:1796-1798.
14. He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 omicron variant: characteristics and prevention. MedComm. 2021;2:838-845.
15. Chen J, Wang R, Gilby NB, Wei GW. Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Clin Inn Med. 2022;62:412-422.
16. Desingu PA, Nagarajan K, Dhma K. Emergence of omicron third lineage BA.3 and its importance. J Med Virol. 2022;94:1808-1810.
17. Desingu PA, Nagarajan K, Omicron BA.2 lineage spreads in clusters and is concentrated in Denmark. J Med Virol. 2022;94:2360-2364.
18. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215-220.
19. Chen J, Wei GW. Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant. ArXiv [Preprint], arXiv:2202.05031v1; 2022.
20. The New York Times. “Stealth” Omicron is stealthy no more: what’s known about the BA.2 variant. 2022. Accessed April 24, 2022. https://www.nytimes.com/article/omicron-variant-ba2.html
21. Islam MR, Hossain MJ. Detection of SARS-CoV-2 omicron (B.1.1.529) variant has created panic among the people across the world: what should we do right now? J Med Virol. 2022;94:1768-1769.
22. Center for Disease Control and Prevention. COVID-19 data tracker. 2022. Accessed April 25, 2022. https://covid.cdc.gov/covid-data-tracker/#variant-proportions
23. Rotondi JC, Martini F, Maritati M, et al. Advanced Molecular and immunological diagnostic methods to detect SARS-CoV-2 infection. Microorganisms. 2022;10:1793.
24. Kumar S, Karuppanan K, Subramaniam G. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: Not applicable to this article.
27. Kumar C, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and delta variant of SARS-CoV-2: a comparative computational study of spike protein. J Med Virol. 2022;94:1641-1649.

25. Wilson C. Omicron still on the rise. New Sci. 2022:255:7.

24. Ai J, Wang X, He X, et al. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.2, and BA.3 sub-variations. Cell Host Microbe. 2022;386:1532-1546.

23. Veneti L, Bais H, Bráthre Kristoffersen A, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 omicron BA.1 variant compared with the delta variant, Norway, December 2021 to January 2022. Euro Surveill. 2022;27:2200077.

22. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5. Nature. Published online July 5, 2022. doi:10.1038/s41586-022-05053-w.

21. Eggink D, Andeweg SP, Vennema H, et al. Increased risk of infection with SARS-CoV-2 omicron BA.1 compared with delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Euro Surveill. 2022;27:2101196.

20. Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022;387:86-88.

19. Bellussi L, Grubbs G, Zahra FT, et al. Antibody affinity and cross-variant neutralization of SARS-CoV-2 omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. Nat Commun. 2022;13:4647.

18. Huang M, Wu L, Zheng A, et al. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. Immunity. 2022;55:1501-1514.e3.

17. Kouroade C, Zou J, Xia H, et al. Neutralization of omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. Nat Commun. 2022;13:3602.

16. Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 omicron sublineages. Nature. 2022;598:533-536.

15. Ai J, Wang X, He X, et al. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe. Published online May 8, 2022. doi:10.1016/j.chom.2022.05.001.

14. Rabiu Islam M, Nareen W, Anjum R, et al. Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health. Clin Pathol. 2022;63:202010X221124908.

13. CNBC. New omicron XE Covid variant first detected in the UK spreads to Japan as cases rise. 2022. Accessed April 25, 2022. https://www.cnbc.com/2022/04/12/new-omicorn-xe-variant-detected-in-japan-as-uk-cases-rise-.html

12. Forbes, Forbes. Here’s what we know about Omicron XE. — The new Covid variant found in the U.K. 2022. Accessed April 25, 2022. https://www.forbes.com/sites/roberthartt/2022/04/05/heres-what-we-know-about-omicron-xe-the-new-covid-variant-found-in-the-uk/?sh=721d9b6a20c

11. CNBC. UK has detected a new Covid variant. Here’s what we know so far about omicron XE. Accessed April 25, 2022. https://www.cnbc.com/2022/04/06/uk-has-detected-a-new-covid-variant-heres-what-we-know-so-far-about-omicorn-xe.html

10. Basky G, Vogel L. XE, XD & XF: what to know about the omicron hybrid variants. CMAJ. 2019;191:E654-E655.

9. Rahimi F, Talebi Bezmim Abadi A. Detection of the XE subvariant of SARS-CoV-2: a perspective. Int J Surg. 2022;101:106642.

8. Andrews N, Snow J, Kirkefom B, et al. Covid-19 vaccine effectiveness against the BA.1 (B.1.529) variant. N Engl J Med. 2022;386:1532-1546.

7. Mahase E. Omicron sub-lineage BA.2 may have “substantial growth advantage,” UKHSA reports. BMJ. 2022;376:o263.

5. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by omicron infection. Nature. 2022;608:593-602.

4. Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387:468-470.

3. Henzien M, Austran B, Pirzol L, et al. A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to beltegravir. Lancet Infect Dis. Published online July 18, 2022. doi:10.1016/S1473-3099(22)00495-9.

2. Yamada B, Kosugi Y, Kimura I, et al. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22:942-943.

1. Ai J, Wang X, He X, et al. Antibody evasion of SARS-CoV-2 omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe. 2022;30:1077-1083.e4.

Yu J, Collier AY, Rowe M, et al. Neutralization of the SARS-CoV-2 omicron BA.1 and BA.2 variants. N Engl J Med. 2022;386:1579-1580.

Zou Y, Huang D, Jiang Q, Guo Y, Chen C. The vaccine efficacy against the SARS-CoV-2 omicron: a systemic review and meta-analysis. Front Public Health. 2022;10:940956.

Daria S, Islam MR. Increased suicidal behaviors among students during COVID-19 lockdowns: a concern of student’s mental health in Bangladesh. J Affect Disord. Rep. 2022;8:100320.

Hossain MJ, Ahmed F, Sarkar MMM, et al. Factors associated with underprivileged E-Learning, session jam phobia, and the subsequent mental distress among students following the extended university closure in Bangladesh. Front Public Health. 2022;9:807474.

Islam MR, Somas MA, Bari MS, Emran TB, Islam MR. COVID-19 and child marriage in Bangladesh: emergency call to action. BMJ Paediatr Open. 2021;5:e001328.

Ether SA, Emon FA, Roknuzzaman A, Rakibuzzaman M, Rahman FI, Islam MR. A cross-sectional study of COVID-19-related knowledge, risk perceptions, and preventive practices among pharmacy students in Bangladesh. SAGE Open Med. 2022;10:20503121211073014.

Islam MR, Qaiyum S, Pakhe SA, Repon MA, Bhuiyan MA. Dataset concerning the mental health of healthcare professionals during COVID-19 pandemic in Bangladesh. Data Brief. 2021;39:107506.

Islam MR, Hossain MJ. Increments of gender-based violence amid COVID-19 in Bangladesh: a threat to global public health and women’s health. Int J Health Plann Manage. 2021;36:2436-2440.

Islam S, Islam T, Islam MR. New Coronavirus variants are creating more challenges to global healthcare system: A Brief Report on the current knowledge. Clin Pathol. 2021;15:2632010X221075584.

Islam MR. Urgent call for mass immunization against coronavirus in Bangladesh. Sci Prog. 2021;104:36804211058562.

Bari MS, Hossain MJ, Ahmmed F, et al. Knowledge, perception, and willingness towards immunization among Bangladeshi population during COVID-19 vaccine rolling period. Vaccines. 2021;9:1449.

Daria S, Islam MR. The SARS-CoV-2 omicron wave is indicating the end of the pandemic phase but the COVID-19 will continue. J Med Virol. 2022;94:2343-2345.

Rottondo JC, Martini F, Maritati M, et al. SARS-CoV-2 infection: new molecular, phylogenetic, and pathogenic insights. Efficacy of current vaccines and the potential risk of variants. Viruses. 2021;13:1687.